^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Hematological Malignancies

    Related cancers:
    1d
    CLL 2000: A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG (clinicaltrials.gov)
    P=N/A, N=2000, Recruiting, German CLL Study Group | Not yet recruiting --> Recruiting
    Enrollment open
    1d
    SWOG-S1117: Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P2, N=282, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    lenalidomide • azacitidine • Zolinza (vorinostat)
    1d
    A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005) (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Apr 2027 --> Dec 2028
    Trial completion date
    |
    nemtabrutinib (MK-1026)
    1d
    ISASOCUT: Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma (clinicaltrials.gov)
    P=N/A, N=74, Active, not recruiting, Poitiers University Hospital | Trial primary completion date: Jul 2026 --> Mar 2026
    Trial primary completion date
    |
    lenalidomide • bortezomib • dexamethasone • isatuximab subcutaneous (SAR650984 SC)
    1d
    Cognitive Impairment in Patients Undergoing Cell- and Antibody-based Immunotherapies for Haematological Malignancies: The COGNITOX Study (clinicaltrials.gov)
    P=N/A, N=225, Not yet recruiting, Aarhus University Hospital
    New trial
    1d
    A Real-world Study on the Efficacy and Safety of Menin Inhibitors as Maintenance After Allo-HSCT (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, The First Affiliated Hospital of Soochow University
    New trial • Real-world evidence
    |
    FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A) • NUP98 (Nucleoporin 98 And 96 Precursor 2)
    |
    FLT3-ITD mutation • NPM1 mutation • KMT2A rearrangement • FLT3-TKD mutation
    1d
    A Study to Evaluate the Safety and Pharmacokinetics of RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P1, N=160, Not yet recruiting, Genentech, Inc.
    New P1 trial
    1d
    EAY131-Z1A: Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A) (clinicaltrials.gov)
    P2, N=53, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    NRAS mutation
    |
    Mektovi (binimetinib)
    1d
    Bio-CAR-T BS Study (clinicaltrials.gov)
    P=N/A, N=45, Recruiting, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | Trial completion date: Apr 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • IO biomarker
    1d
    NP30179: A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma (clinicaltrials.gov)
    P1/2, N=940, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting | Trial completion date: Dec 2029 --> Mar 2029 | Trial primary completion date: Dec 2029 --> Mar 2029
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)
    1d
    BGB-11417-2001-IIT: Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)
    P2, N=47, Active, not recruiting, Shanghai Jiao Tong University School of Medicine | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    cytarabine • azacitidine • daunorubicin • idarubicin hydrochloride • sonrotoclax (BGB-11417)
    1d
    CD70-CAR-NK Cell Therapy for T Cell Lymphoma and Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=25, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK negative